European Medicines Agency confirms positive benefit-risk balance for Champix
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has confirmed that the benefit-risk balance for Champix (varenicline) remains positive, despite the results of a recent meta-analysis of the medicine’s side effects affecting the heart and blood vessels.